Dysmenorrhea Treatment Market: Competitive Strategies, Regional Analysis Forecast 2030
Dysmenorrhea Treatment Market - Overview
Dysmenorrhea refers to the painful menstruation women
experience during their monthly discharging periods. While it is normal for women to have mild
abdominal cramps on the initial days of their menstruation, about 30% of women
experience severe pain along with headaches and nausea that could be termed as
Dysmenorrhea. Over the past decade, the prevalence of Dysmenorrhea is observed
to be growing. Reasons could be environmental changes, change in diet, and lack
of nutritious diet, etc.
However, the cause acting as the driving force to prevail
these conditions is changing and unhealthy lifestyle. Today’s working women
have to cope-up with physical as well as mental stress encountered at both the
fronts – personal (family) and workplace. Growing awareness among women towards
the fact that Dysmenorrhea can now be treated and the availability and
accessibility of treatments are encouraging the increasing number of women to
avail the advantages of these treatments. Resultantly, Dysmenorrhea
market is growing pervasively, becoming a lucrative space.
Acknowledging the exponential growth the market perceives
currently; Market Research Future (MRFR), in its recently published market
forecast asserts that the global Dysmenorrhea
Treatment Market will reach USD 8.40 Bn. by 2023, registering a
striking CAGR of 12.28% throughout the forecast period (2017 – 2023). In 2016,
the market had valued at USD 5.68 Bn.
Dysmenorrhea Treatment Market - Segmentations
MRFR has segmented the report into three key dynamics for an
easy grasp and enhanced understanding:-
·
By Type :
Primary and Secondary (Adenomyosis, Endometriosis, Uterine myomas, Cervical
stenosis, Endometrial polyps, and Obstructive malformations of genital tract.).
·
By Treatment: Non-Steroidal
Anti-Inflammatory Drugs (Nsaids), Hormonal, and Combined Oral Contraceptive
among others.
·
By End-User : Hospitals, Clinics,
Diagnostic Centers, and Pharmaceutical Companies among Others.
·
By Regions: North America, Europe, APAC and Rest of the
World.
Global Dysmenorrhea Treatment Market - Competitive Landscape
The competitive market for Dysmenorrhea Treatment is
fragmented with many large and small players operating in the market. Market
players incorporate acquisition, collaboration, expansion, technology launch
and strategic partnership. These players substantially invest in R&D and
clinical trials to develop effective drugs.
To help accelerate pharmaceutical innovations and to gain a
better understanding of the conditions, these pharma companies collaborate with
academia and the biotech industry partners who can contribute cutting-edge
technologies and specialized knowledge.
These collaborations are one of the innovation strategies of market
players. Companies can leverage the latest scientific knowledge and translate
it into innovative medicines through partnering. These partnerships can kindle
the innovative impulses that advance medicine and benefit patients as well as
partners.
List of Key Companies Covered in this report:
·
Johnson & Johnson (US),
·
GlaxoSmithKline PLC (UK),
·
Hoffmann-La Roche Ltd (Switzerland),
·
Bayer AG (Germany),
·
Focus Consumer Healthcare, LLC (US),
·
Novartis AG (Switzerland),
·
Pfizer, Inc. (US),
·
Reckitt Benckiser Group plc. (UK),
·
Sanofi S.A. (France),
·
Viatris Inc. (US)
Global Dysmenorrhea Treatment Market - Regional Analysis
Globally North America leads the Dysmenorrhea Treatment
market with the significant market share. The Market is expected to grow
phenomenally from 2017 to 2023. Attributing to the favorable reimbursement
scenario and higher expenditure on healthcare the market is expected to
perceive a healthy growth.
The factor contributing to the market growth include
increasing prevalence of issues and disorders associated with women’s
reproductive system fuelled by the changing lifestyle and growing awareness
towards the availability of the treatments. The US, backed by the technological
advances and availability of funding for the development of new therapeutics
and treatment accounts for the major contributor to the market growth.
Europe emerging as a lucrative market for Dysmenorrhea
Treatment will expand registering a phenomenal CAGR. The resurging economy in the region is
expected to foster the regional market growth, increasing per capita healthcare
expenditures. The financial support provided by private and governments bodies
for R&D activities and new improved reimbursement policies in healthcare
will fuel the Dysmenorrhea Treatment market in Europe.
Industry/Innovation/ Related News:
·
January 04, 2018 – Pfizer Inc. (US) a
pharmaceutical conglomerate announced the partnership with 23andMe (US), a
privately held personal genomics and biotechnology company to aid understanding
of depression, dysmenorrhea and the genetic heterogeneity of lupus and
inflammatory bowel disease. Pfizer believes that such collaborations will help
it to potentially usher in a new era of patient care defined by targeted
research methods and ultimately better patient outcomes.
About US:
Market Research Future (MRFR) enable customers to unravel
the complexity of various industries through Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed
Research (CFR), and Market Research & Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media
Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013
Comments
Post a Comment